Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.

van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB.

Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.

PMID:
28982110
3.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

4.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

5.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

6.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

7.

Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.

Pastushenko I, Van den Eynden GG, Vicente-Arregui S, Prieto-Torres L, Alvarez-Alegret R, Querol I, Dirix LY, Carapeto FJ, Vermeulen PB, Van Laere SJ.

Am J Dermatopathol. 2016 May;38(5):338-46. doi: 10.1097/DAD.0000000000000488.

PMID:
26909582
8.

Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.

Eefsen RL, Engelholm L, Willemoe GL, Van den Eynden GG, Laerum OD, Christensen IJ, Rolff HC, Høyer-Hansen G, Osterlind K, Vainer B, Illemann M.

Int J Cancer. 2016 Apr 1;138(7):1777-84. doi: 10.1002/ijc.29904. Epub 2015 Nov 17.

9.

Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy.

Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Høyer-Hansen G, Vainer B, Osterlind K, Illemann M.

Cancer Microenviron. 2015 Aug;8(2):93-100. doi: 10.1007/s12307-015-0172-z. Epub 2015 Aug 14.

10.

Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma.

Pastushenko I, Vermeulen PB, Vicente-Arregui S, Van den Eynden GG, Alvarez-Alegret R, Querol I, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

J Cutan Pathol. 2015 Oct;42(10):699-711. doi: 10.1111/cup.12571. Epub 2015 Sep 11.

PMID:
26264662
11.

Growth pattern of colorectal liver metastasis as a marker of recurrence risk.

Eefsen RL, Vermeulen PB, Christensen IJ, Laerum OD, Mogensen MB, Rolff HC, Van den Eynden GG, Høyer-Hansen G, Osterlind K, Vainer B, Illemann M.

Clin Exp Metastasis. 2015 Apr;32(4):369-81. doi: 10.1007/s10585-015-9715-4. Epub 2015 Mar 31.

PMID:
25822899
12.

Melanomas arising on skin with chronic sun-induced damage exhibit low degree of angiogenesis and lymphangiogenesis.

Pastushenko I, Vicente-Arregui S, Van den Eynden GG, Gracia-Cazaña T, Carapeto FJ, Alvarez-Alegret R, Dirix LY, Vermeulen PB, Van Laere S.

Am J Dermatopathol. 2015 Jun;37(6):451-4. doi: 10.1097/DAD.0000000000000265.

PMID:
25747811
13.

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Peeters DJ, Brouwer A, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Cancer Lett. 2015 Jan 28;356(2 Pt B):872-9. doi: 10.1016/j.canlet.2014.10.039. Epub 2014 Nov 4.

PMID:
25449778
14.

Tumor stromal phenotypes define VEGF sensitivity--letter.

Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, Brodt P; Liver Metastasis Research Network.

Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158. No abstract available.

15.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, Veer LV, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group.

Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.

16.

Squamous cell carcinomas of the skin explore angiogenesis-independent mechanisms of tumour vascularization.

Pastushenko I, Gracia-Cazaña T, Vicente-Arregui S, Van den Eynden GG, Ara M, Vermeulen PB, Carapeto FJ, Van Laere SJ.

J Skin Cancer. 2014;2014:651501. doi: 10.1155/2014/651501. Epub 2014 May 6.

17.

Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.

Pastushenko I, Vermeulen PB, Van den Eynden GG, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

Br J Dermatol. 2014 Aug;171(2):220-33. doi: 10.1111/bjd.12973. Epub 2014 Jul 26. Review.

PMID:
24641095
18.

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.

Br J Cancer. 2014 Jan 21;110(2):375-83. doi: 10.1038/bjc.2013.743. Epub 2013 Dec 24.

19.

Histopathological evaluation of resected colorectal cancer liver metastases: what should be done?

Van den Eynden GG, van Dam PJ, Stroobants S, Dirix L, Vermeulen P; Liver Metastasis Research Network.

Histopathology. 2014 Jan;64(2):315-6. doi: 10.1111/his.12259. Epub 2013 Nov 6. No abstract available.

PMID:
24330151
20.

The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications.

Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR, Brodt P.

Cancer Res. 2013 Apr 1;73(7):2031-43. doi: 10.1158/0008-5472.CAN-12-3931. Epub 2013 Mar 27. Review.

21.

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Br J Cancer. 2013 Apr 2;108(6):1358-67. doi: 10.1038/bjc.2013.92. Epub 2013 Mar 7.

22.

Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases.

Eefsen RL, Van den Eynden GG, Høyer-Hansen G, Brodt P, Laerum OD, Vermeulen PB, Christensen IJ, Wettergren A, Federspiel B, Willemoe GL, Vainer B, Osterlind K, Illemann M.

J Oncol. 2012;2012:907971. doi: 10.1155/2012/907971. Epub 2012 Aug 2.

23.

The histological growth pattern of colorectal cancer liver metastases has prognostic value.

Van den Eynden GG, Bird NC, Majeed AW, Van Laere S, Dirix LY, Vermeulen PB.

Clin Exp Metastasis. 2012 Aug;29(6):541-9. doi: 10.1007/s10585-012-9469-1. Epub 2012 Apr 3.

PMID:
22476470
24.

Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome.

Vanlander AV, Jorens PG, Smet J, De Paepe B, Verbrugghe W, Van den Eynden GG, Meire F, Pauwels P, Van der Aa N, Seneca S, Lissens W, Okun JG, Van Coster R.

Acta Anaesthesiol Scand. 2012 Apr;56(4):520-5. doi: 10.1111/j.1399-6576.2011.02628.x. Epub 2012 Jan 19.

PMID:
22260353
25.

VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY.

Clin Transl Oncol. 2011 Nov;13(11):805-8. doi: 10.1007/s12094-011-0737-3.

PMID:
22082645
26.

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer.

Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY.

Br J Cancer. 2011 Apr 26;104(9):1472-7. doi: 10.1038/bjc.2011.122. Epub 2011 Apr 5.

27.

Rapidly evolving liver decompensation with some remarkable features 14 years after biliopancreatic derivation: a case report and literature review.

van Dongen JL, Michielsen PP, Van den Eynden GG, Pelckmans PA, Francque SM.

Acta Gastroenterol Belg. 2010 Jan-Mar;73(1):46-51. Review.

PMID:
20458850
28.

Propofol infusion syndrome with arrhythmia, myocardial fat accumulation and cardiac failure.

Jorens PG, Van den Eynden GG.

Am J Cardiol. 2009 Oct 15;104(8):1160-2. doi: 10.1016/j.amjcard.2009.05.065.

PMID:
19801042
29.

Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.

Baldewijns MM, van Vlodrop IJ, Smits KM, Vermeulen PB, Van den Eynden GG, Schot F, Roskams T, van Poppel H, van Engeland M, de Bruïne AP.

Cell Oncol. 2009;31(5):371-82. doi: 10.3233/CLO-2009-0482.

30.

Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Trinh XB, Van Marck EA, Dirix LY, Vermeulen PB.

Int J Cancer. 2009 Sep 15;125(6):1494-6. doi: 10.1002/ijc.24524. No abstract available.

31.

A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity.

Baldewijns MM, Roskams T, Ballet V, Van den Eynden GG, Van Laere SJ, Van der Auwera I, Lerut E, De Bruïne AP, Thijssen VL, Vermeulen PB, van Poppel H.

BJU Int. 2009 Jun;103(12):1626-31. doi: 10.1111/j.1464-410X.2008.08272.x. Epub 2009 Jan 12.

32.

Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype.

Van der Auwera I, Van Laere SJ, Van den Bosch SM, Van den Eynden GG, Trinh BX, van Dam PA, Colpaert CG, van Engeland M, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2008 Nov 18;99(10):1735-42. doi: 10.1038/sj.bjc.6604705. Epub 2008 Oct 7.

33.

Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.

Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, Foekens JA.

Clin Cancer Res. 2008 May 15;14(10):2944-52. doi: 10.1158/1078-0432.CCR-07-4397.

34.

Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node.

Van den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5391-7.

35.

Letter to the editor: Lymphangiogenesis in primary breast cancer.

Van den Eynden GG, Van der Auwera I, Colpaert CG, Dirix LY, Van Marck EA, Vermeulen PB.

Cancer Lett. 2007 Oct 28;256(2):279-81; author reply 283-4. Epub 2007 Aug 21. No abstract available.

PMID:
17714860
36.

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2007 Sep 3;97(5):659-69. Epub 2007 Aug 14.

37.

Comparison of molecular determinants of angiogenesis and lymphangiogenesis in lymph node metastases and in primary tumours of patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Trinh XB, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

J Pathol. 2007 Sep;213(1):56-64.

PMID:
17674348
38.

A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph)angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation.

Van den Eynden GG, Colpaert CG, Couvelard A, Pezzella F, Dirix LY, Vermeulen PB, Van Marck EA, Hasebe T.

Histopathology. 2007 Oct;51(4):440-51. Epub 2007 Jun 26. Review.

PMID:
17593207
39.

High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.

Baldewijns MM, Thijssen VL, Van den Eynden GG, Van Laere SJ, Bluekens AM, Roskams T, van Poppel H, De Bruïne AP, Griffioen AW, Vermeulen PB.

Br J Cancer. 2007 Jun 18;96(12):1888-95. Epub 2007 May 15.

40.

Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Gilles L, Burn JL, Colpaert C, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB.

Clin Exp Metastasis. 2007;24(1):13-23. Epub 2007 Feb 13.

PMID:
17295094
41.

PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.

Van den Eynden GG, Neyret A, Fumey G, Rizk-Rabin M, Vermeulen PB, Bouizar Z, Body JJ, Dirix LY.

Bone. 2007 Apr;40(4):1166-71. Epub 2006 Dec 22.

PMID:
17188588
42.

Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Huygelen V, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2006 Nov 20;95(10):1362-6. Epub 2006 Oct 31.

43.

Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56.

44.

Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2006 Jun 5;94(11):1643-9.

45.

Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.

Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB.

Clin Cancer Res. 2005 Nov 1;11(21):7637-42.

46.

Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.

Van Laere SJ, Van den Eynden GG, Van der Auwera I, Vandenberghe M, van Dam P, Van Marck EA, van Golen KL, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2006 Feb;95(3):243-55. Epub 2005 Oct 27.

47.

Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer.

Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, Turley H, Harris AL, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA.

Br J Cancer. 2005 Nov 14;93(10):1128-36.

48.

Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.

Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL.

Breast Cancer Res Treat. 2006 Feb;95(3):219-28. Epub 2005 Oct 22.

49.

Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.

Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Breast Cancer Res Treat. 2005 Oct;93(3):237-46.

PMID:
16172796
50.

Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification.

Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY.

Clin Cancer Res. 2004 Dec 1;10(23):7965-71.

Supplemental Content

Loading ...
Support Center